The Daily

American biotech firm Moderna has released early results from its phase 3 clinical trials, announcing on Monday that its COVID vaccine has an efficacy rate of 94.5%. The trial had 30,000 participants and of those that received the vaccine only 5% developed COVID19 whereas of those that were given the placebo, 90% developed COVID19. This promising result means that there are now two vaccines that have shown promising preliminary results as biotech firm Pfizer announced last week that their trial had also shown 90% effectiveness.

The Daily spoke to professor of Immunology from RMIT University, Magdalena Plebanksi to discuss the latest on the COVID-19 vaccine trials.